Cyclin-dependent kinase inhibitors play a critical role in regulating progression of the eukaryotic cell through the cell cycle by associating with protein complexes composed of cyclins and cyclin-dependent kinases and thus downmodulating the activity of the cyclindependent kinases (1) . Pathways involving cyclin-dependent kinase inhibitors are frequently disrupted in cancer cells, and this disruption leads to abnormal regulation of the cell cycle. Overexpression of cyclin-dependent kinase inhibitors leads to the arrest of cells at one of the checkpoints in the cell cycle (2) . Therefore, using cyclindependent kinase inhibitors for gene therapy of cancer is intuitively attractive because it has the potential to inhibit tumor growth (3) . Thus far, adenoviral vectors expressing the cyclin-dependent kinase inhibitors p16 INK4A and p21 waf1/cip1 have been evaluated in preclinical models for their suitability for gene therapy of cancer (3) (4) (5) (6) (7) (8) (9) .
We have constructed an adenoviral vector expressing p27 Kip1 and observed that it is statistically significantly better at causing growth arrest in several breast cancer cell lines than is another adenoviral vector that expresses p21 waf1/cip1 (2) . More interestingly, we have recently discovered that overexpression of p27 Kip1 induces apoptosis in cancer cells, an activity that is not associated with p16
INK4A or p21 waf1/cip1 (8, 10) . In fact, p21 waf1/cip1 has been reported to have a protective effect against apoptosis (11,12). These observations led us to examine the effects of adenoviral expression of p27
Kip1 in an in vivo breast cancer model system.
We injected MDA-MB-231 human breast cancer cells into athymic nude mice to establish subcutaneous tumor nodules and then studied the effects of intratumoral injections of various adenoviral vectors on these mice and their tumors. Ad␤gal, a recombinant adenovirus that expresses Escherichia coli ␤-galactosidase, was used to establish the infectability of the MDA-MB-231 cells. As shown in Fig. 1 , A, after in vitro infection with Ad␤gal at a multiplicity of infection of 100 plaqueforming units per cell, all cells treated with X-gal (5-bromo-4-chloro-3-indolyl ␤-D-galactoside) were colored blue. Thus, adenoviral vectors can transduce a transgene into this cell line with a high degree of efficiency. Next, we injected the Ad␤gal virus intratumorally into established MDA-MB-231 tumor nodules in athymic nude mice. At various intervals, animals were killed, and their tumors were excised and evaluated for ␤-galactosidase expression as described in Fig. 1 . Blue-colored tumor nodules could be easily observed up to 14 days after infection (Fig. 1, B) . Microscopic examination of sections from these blue tumors revealed that the blue color was present intracellularly, thus establishing that the transgene is expressed in the cells (Fig. 1, C) . (All animal experiments reported in this study were carried out in accordance with institutional guidelines.)
To study the effect of adenovirusmediated overexpression of p27 Kip1 , we injected subcutaneous tumor nodules four times with phosphate-buffered saline (PBS) (mock injection) or with one of the following adenoviral vectors: AdNull, a control vector that does not express any transgene; Adp27, a recombinant adenovirus that expresses p27 Kip1 ; and Adp21, an adenoviral vector that expresses p21 waf1/cip1 . From our previous experience (unpublished results), we used a dose schedule of 2.5 × 10 8 plaque-forming units of virus per dose per day for 4 days, for a total viral dose of 10 9 plaque-forming units for all three viruses. Tumors were measured every 5 days for a period of 30 days as described previously (13) . On day 0, average tumor volumes (±standard deviation) in this experiment were 18 (±4) mm 3 , and on day 30, average tumor volumes were 1320 (±387) mm 3 in the Adp27-treated group compared with 4190 (±563) mm 3 , 3335 (±672) mm 3 , and 3117 (±238) mm 3 in the PBS-, AdNull-, and Adp21-treated groups, respectively. In other words, tumors in the Adp27-treated group were only one third as large as tumors in the mock-treated group. In this experiment, in accord with institutional guidelines, animals were killed on the day that their tumors measured more than 20 mm in one dimension; i.e., all animals were killed when the size of their tumor(s) reached 20 mm. There were no deaths from ''other causes'' in any group. Data from all animals were included in the calculation of average tumor volume. Data from the animals that were killed because of their large tumors were analyzed as if the animals had tumor volumes that were equal to the volume of their last measurement (20 mm in one dimension). Data from the tumor-free animals in the treated groups were analyzed as if the animals had tumor volumes equal to zero.
Infection with Adp27 caused tumor regression in the majority of the animals. As shown in Fig. 2 , A, 36% of the animals that received Adp27 became tumor free by day 5 after completing the injections as compared with none of the animals in the control (mock treatment) groups. This proportion steadily increased to more than 60% by day 15. Of the animals that received AdNull or Adp21, 18% became tumor free by day 15. However, all PBS-injected animals had rapidly growing tumors that necessitated euthanasia in 60% of the animals by day 30. A representative pair of animals that received AdNull or Adp27 is shown in Fig. 2, B . Similar results were obtained when this experiment was repeated. To investigate whether these Adp27 effects were a general phenomenon, we examined the effect of Adp27 Fig. 1. MDA-MB 6 cells. Tumors were injected with Ad␤gal (10 9 plaqueforming units). At various times, the tumor-bearing mice were killed and their tumors were excised, fixed in formaldehyde and glutaraldehyde for 4 hours, and stained for 4 hours as described above. Tumors at the following times are shown: day 1 after AdNull infection (left), day 1 after Ad␤gal infection (middle), and day 14 after Ad␤gal infection (right). C) For histologic examination, Ad␤gal-infected tumors that showed ␤-galactosidase activity were sectioned (5-m sections), counterstained with hematoxylin-eosin, and examined microscopically at magnifications of ×40 (left) and ×200 (right). in another human breast cancer model system that used MDA-MB-468 cells. Our laboratory had shown previously that these cells can also be infected with recombinant adenoviral vectors (14) . MDA-MB-468 cells were injected subcutaneously into nude mice (3 × 10 6 cells per animal), and the established tumors were injected with Adp27 or AdNull by use of the dose schedule described above for the MDA-MB-231 model system. In the MDA-MB-468 system, we also found that Adp27 infection induced tumor regressions in the majority of the animals (Fig. 2, A) . Thus, by day 30 in the mock-infected group, 100% of the mice were tumor bearing; in the Adp27-treated group, 67% of the mice were tumor free; and in the AdNull-treated group, only 25% of the mice were tumor free. These results clearly indicate the efficacy of Adp27 in the MDA-MB-468 model system.
We also investigated whether injecting Adp27 directly into the tumors can induce apoptosis of the tumor cells in vivo as documented in in vitro studies (10) . Adp27 was injected into MDA-MB-231 tumors; 48 hours later, the tumors were examined to determine whether apoptotic cells were present. As shown in Fig. 2 , C, tumors that received a control virus had a minimum number of cells that were undergoing apoptosis, but tumors that received Adp27 had many more cells that appeared to be undergoing apoptosis. It is likely that Adp27-mediated apoptosis might be playing a crucial role in the therapeutic effect of Adp27 observed in this breast cancer model.
In this study, we examined the effects of adenovirus-mediated overexpression of p27
Kip1 on the growth of MDA-MB-231 and MDA-MB-468 human breast cancer xenografts in nude mice. After four doses of Adp27, a complete response rate of about 60% was observed. However, it is somewhat puzzling to us why the remaining 40% of the tumors evaded the tumoricidal effect of Adp27.
Perhaps the injection technique was not completely standardized and some tumors did not receive the proper dose, perhaps the vector was poorly distributed in the tumors, or perhaps there were biologic variations among the animals. Nevertheless, a 60% response rate is comparable to our unpublished results and the experience of other groups with adenovirus-mediated overexpression of human wild-type p53 in similar animal models (13, 15, 16 ) and substantially better than the results of overexpression of p21 waf1/cip1 or p16 INK4A (3) (4) (5) (6) (7) (8) (9) . This difference may be accounted for by the induction of apoptosis after p27
Kip1 overexpression, a property it shares with p53 but not with p21 waf1/cip1 and p16 INK4A . However, it should be noted that p16 INK4A in combination with wild-type p53 has been demonstrated to induce apoptosis in cancer cells (9) .
Adenoviral vectors expressing human wild-type p53 are currently being evaluated in many clinical studies in patients with advanced cancer (16) . From the encouraging results presented here, gene therapy of cancer with adenoviral transfer of p27 Kip1 , alone or combined with other tumor suppressor genes, or other strategies of cancer gene therapy appears to be a promising treatment option.
